Intrinsiqq
Nuo Therapeutics Inc. logo

Nuo Therapeutics Inc.

AURX

Compare
⚠ Showing the latest available close (Nov 5, 2026, 3 days ago). Our price provider hasn't published a newer EOD for this ticker yet. Price-dependent metrics (P/E, P/FCF, yield) may not reflect current market conditions.

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$52M
EPS-$0.04
P/E-26.18
P/FCF-21.18
EV/EBITDA-29.69
FCF Yield–
Div. Yield–
Net Debt/FCF0.2x
Nuo Therapeutics Inc. intrinsic value
52-Week Range
$0.77$2.55

Profitability & Returns

Revenue (TTM)

$5M

▲ +142.7% YoY

Net Income (TTM)

-$2M

▼ -8.1% YoY

Op. Margin

-33.32%

▲ +104.1pp YoY

ROIC

-1559.40%

▼ -316.0pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$2M

▲ +52.2% YoY

Op. Cash Flow (TTM)

-$2M

▲ +61.2% YoY

Net Debt

-$389K

Net Cash Position

Cash & Equiv.

$449K

Continue Research

Peers

Surgical & Medical Instruments & Apparatus · Pick stocks to compare with AURX

CompareIntrinsic value
TNONTenon Medical Inc.
$1.64+0.00%40
LUCDLucid Diagnostics Inc.
$0.40+2.04%44
INBSIntelligent Bio Solutions Inc.
$1.97+11.93%40
PSTVPlus Therapeutics Inc
No recent price28
PMIPicard Medical, Inc.
$9.00+14.65%30
ECIAEncision Inc.
$0.01-56.33%14
ICCMIceCure Medical Ltd.
$0.68-1.30%43
USAQQHSLab Inc.
$0.32+0.00%49

Nuo Therapeutics (AURX) in four numbers

Fair value (revenue)
$3.71
Price $1.07 is 71% below it.
Intrinsic Value
Quality score
40/100
Best check: revenue growth, 160.9%. Weakest: return on capital, -1559.4%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-26.18
Negative: a loss over the last twelve months. Price to free cash flow -21.18.
Financials

Questions about Nuo Therapeutics

Is Nuo Therapeutics (AURX) overvalued?

At $1.07, Nuo Therapeutics' price is 71% below the $3.71 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

What is Nuo Therapeutics' fair value?

Intrinsiqq's calculator puts Nuo Therapeutics' fair value at $3.71 a share. It grows revenue per share 30% a year for 5 years, applies an exit P/S of 15, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $2.78. Every input can be changed on the Intrinsic Value tab.

Is Nuo Therapeutics a high-quality business?

Nuo Therapeutics scores 40 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 6 checks computed from SEC filings. Its best check is revenue growth at 160.9%, and its weakest is return on capital at -1559.4%. The Quality tab shows every check against its target.

Does Nuo Therapeutics (AURX) pay a dividend?

No. Nuo Therapeutics (AURX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 12 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 5 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in AURX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing AURX

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.